- Home
- TGS vs VRNA Comparison
TGS vs VRNA Comparison
Compare TGS & VRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGS
- VRNA
- Stock Information
- Founded
- TGS 1992
- VRNA 2005
- Country
- TGS Argentina
- VRNA United Kingdom
- Employees
- TGS N/A
- VRNA N/A
- Industry
- TGS Natural Gas Distribution
- VRNA Biotechnology: Pharmaceutical Preparations
- Sector
- TGS Utilities
- VRNA Health Care
- Exchange
- TGS Nasdaq
- VRNA Nasdaq
- Market Cap
- TGS 4.1B
- VRNA 3.4B
- IPO Year
- TGS N/A
- VRNA 2017
- Fundamental
- Price
- TGS $28.27
- VRNA $51.89
- Analyst Decision
- TGS
- VRNA Strong Buy
- Analyst Count
- TGS 0
- VRNA 7
- Target Price
- TGS N/A
- VRNA $50.57
- AVG Volume (30 Days)
- TGS 339.7K
- VRNA 1.4M
- Earning Date
- TGS 03-03-2025
- VRNA 02-27-2025
- Dividend Yield
- TGS N/A
- VRNA N/A
- EPS Growth
- TGS 7.75
- VRNA N/A
- EPS
- TGS 0.21
- VRNA N/A
- Revenue
- TGS $570,314,127.00
- VRNA $5,624,000.00
- Revenue This Year
- TGS N/A
- VRNA N/A
- Revenue Next Year
- TGS N/A
- VRNA $550.30
- P/E Ratio
- TGS $31.11
- VRNA N/A
- Revenue Growth
- TGS N/A
- VRNA 1127.95
- 52 Week Low
- TGS $11.81
- VRNA $11.39
- 52 Week High
- TGS $34.37
- VRNA $55.42
- Technical
- Relative Strength Index (RSI)
- TGS 42.73
- VRNA 64.25
- Support Level
- TGS $29.30
- VRNA $43.44
- Resistance Level
- TGS $31.17
- VRNA $55.42
- Average True Range (ATR)
- TGS 1.88
- VRNA 3.32
- MACD
- TGS -0.44
- VRNA 0.40
- Stochastic Oscillator
- TGS 6.44
- VRNA 70.52
About TGS Transportadora de Gas del Sur SA TGS
Transportadora de Gas del Sur SA is a transporters of natural gas in Latin America. The company's operating segments include Natural Gas Transportation, Midstream, Telecommunications, and Production and Commercialization Liquids, Other Services, and Telecommunications. It generates maximum revenue from the Production and Commercialization of the Liquids segment. Geographically, it derives the majority of its revenue from Argentina.
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.